These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 11911296

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical Usefulness of the Histoculture Drug Response Assay for Breast Cancer.
    Hoffman RM, Tanino H.
    Methods Mol Biol; 2018; 1760():93-100. PubMed ID: 29572797
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR, Hoffman RM.
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA, Romain S, Look MP, Martin PM, Klijn JG.
    Cancer Res; 2001 Feb 15; 61(4):1421-5. PubMed ID: 11245445
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potential of the histoculture drug-response assay to contribute to cancer patient survival.
    Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H.
    Clin Cancer Res; 1995 Dec 15; 1(12):1537-43. PubMed ID: 9815954
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J, Lucas R, Sánchez J, Ruibal A, Tejerina A, Martín M.
    Anticancer Res; 2000 Dec 15; 20(6B):4373-7. PubMed ID: 11205274
    [Abstract] [Full Text] [Related]

  • 12. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
    Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T.
    J Clin Oncol; 2007 Feb 01; 25(4):411-7. PubMed ID: 17179098
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [CMF or CAF combination chemotherapy for breast cancer].
    Ota J.
    Gan To Kagaku Ryoho; 1996 Dec 01; 23(14):1886-90. PubMed ID: 8978791
    [Abstract] [Full Text] [Related]

  • 15. Heterogeneity of drug resistance in human breast and ovarian cancers.
    Kern DH.
    Cancer J Sci Am; 1998 Dec 01; 4(1):41-5. PubMed ID: 9467045
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues.
    Kubota T, Furukawa T, Tanino H, Oura S, Murata H, Yuasa S, Morita K, Ueno J, Kozakai R, Yano T.
    Anticancer Res; 1998 Dec 01; 18(2A):967-72. PubMed ID: 9615748
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
    Abe O, Izuo M, Enomoto K, Kubo K, Koyama H, Sakai K, Terasawa T, Tominaga T, Nomura Y.
    Gan To Kagaku Ryoho; 1982 May 01; 9(5):866-73. PubMed ID: 7184431
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
    Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T.
    Oral Oncol; 2007 Sep 01; 43(8):749-56. PubMed ID: 17112769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.